Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
NCT01069471
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Shigellosis
Interventions
BIOLOGICAL:
Shigella vaccine
Sponsor
GlycoVaxyn AG